	FORM	+	SEC		LJ A ington, I		<b>EXCHA</b> 0549	INGE		VIIVII	33101	N	OMB	APPRC	VAL				
	this box if no l		ST		IT OF CHANGES IN BENEFICIAL OWN								ERS	<b>SHIP</b>		B Numbe		3235-0287	
to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed						pursuant to Section 16(a) of the Securities Exchange Act of 1934										imated av irs per res	erage burd sponse:	en 0.5	
Instruc				Flieu						Company Act									
1. Name and Address of Reporting Person <sup>*</sup> <u>Ho Carole</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Denali Therapeutics Inc.</u> [ DNLI ]								(Che	lationship ck all appli Direct	icable)	Ū	10% O			
	(Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 03/30/2020								X below) below) Chief Medical Officer						
	(Street) SOUTH SAN FRANCISCO CA 94080				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					on	
(City)	(Si	ate)	(Zip)																
		Tab	le I - N	lon-Deriva	tive	Secu	rities A	cquire	d, D	isposed o	of, or E	Benefi	ciall	y Owne	ed				
Date			2. Transactio Date (Month/Day/\	(ear)	ar) 2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3,			4 and 5) Securiti Benefici		s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code	v	Amount	(A) or (D)	Price		Transacti (Instr. 3 a			ľ	•	
Common Stock 03/30/2				03/30/20	20			<b>S</b> <sup>(1)</sup>		1,428	D	\$19.4	<b>48</b> <sup>(2)</sup>	2,8	22	I	>		
Common Stock													46,8	375	D	(3)			
Common Stock													25,0	000	1		See ootnote <sup>(4)</sup>		
Common Stock												7		,934			See ootnote <sup>(5)</sup>		
		٦	Table II	- Derivati (e.g., pu						posed of , converti				Owned	l				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	cise (Month/Day/Year) f ive		3A. Deemed Execution Date, if any (Month/Day/Year)		action (Instr.	5. Number of Derivativ Securitie Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	Expi e (Mor s	ration	ercisable and Date //Year)	Amou Secur Unde Deriv Secur	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Price of Derivative Security (Instr. 5)		e ( es li ally i	LO. Dwnership Form: Direct (D) Dr Indirect I) (Instr. 4)	Beneficia ) Ownersh ct (Instr. 4)	
		1		I			<u> </u>							I					

Explanation of Responses:

1. Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.

Code V

2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from \$19.44 to \$19.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

(A) (D)

Date Exercisable Expiration Date

3. The shares are held of record by Carole Ho and Rajat Rohatgi.

4. Shares held of record by The Rohatgi-Ho Irrevocable GST Trust, for which Reporting Person serves as trustee.

5. The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.

## **Remarks:**

/s/ Tyler Nielsen, by power of 04/01/2020

<u>attorney</u>

\*\* Signature of Reporting Person Date

of Shares

Title

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.